SUCCESSFUL TREATMENT OF VENTILATOR ASSOCIATED PNEUMONIA CAUSED BY MULTIDRUG RESISTANT ACINETOBACTER BAUMANNII WITH A COMBINATION THERAPY OF CSE1034 AND COLISTIN: A CASE REPORT.
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i2.21619Keywords:
CSE1034, Colistin, Pneumonia, Acinetobacter baumannii, CarbapenamasesAbstract
 Objective: One of the major causes of ventilator-associated pneumonia (VAP) in hospital settings is Acinetobacter baumannii. The propensity of acquiring antimicrobial resistance rapidly through a multiple number of mechanisms makes the selection of an appropriate empirical antimicrobial agent exceedingly challenging for this pathogen.
Methods: The present case report explores the option of treating VAP infection due to carbapenem-resistant pathogens with antibiotic adjuvant entities.
Results: We present a case of VAP due to carbapenem-resistant A. baumannii that was successfully treated with CSE-1034 and colistin combination therapy.
Conclusion: Early recognition and appropriate antibiotic therapy are essential to eliminate poor outcomes in multidrug-resistant (MDR) bacterial infections. The present case highlights the antibiotic adjuvant entity CSE-1034†as an empiric option for the treatment of VAP due to MDR A. baumannii in intensive care unit.
Downloads
References
Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:3471-84.
Arjuna A, Nandi D. Acinetobacter main cause of hospital acquired infections: A review. Asian J Pharm Clin Res 2017;10:53-6.
Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: Evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med 2015;36:85-98.
Almomani B, Al-Gharaibeh R, Al-Mahasneh F, Samrah S. Multidrug resistant Acinetobacter baumannii in ventilator associated pneumonia: Prevalence and predictors of mortality. Eur Respir J 2014;44:2071.
Siegel RE. Emerging gram-negative antibiotic resistance: Daunting challenges, declining sensitivities, and dire consequences. Respir Care 2008;53:471-9.
Ganguly NK, Arora NK, Chandy SJ, Fairoze MN, Gill JP, Gupta U, et al. Rationalizing antibiotic use to limit antibiotic resistance in India. Indian J Med Res 2011;134:281-94.
Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. Acinetobacter baumannii 2002-2008: Increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist 2010;16:209-15.
Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. Clin Microbiol Infect 2016;22 Suppl 1:S9-14.
Lin MF, Lan CY. Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases 2014;2:787-814.
Kornum JB, Thomsen RW, Riis A, Lervang HH, Schønheyder HC, Sørensen HT. Type 2 diabetes and pneumonia outcomes: A population-based cohort study. Diabetes Care 2007;30:2251-7.
Song SW, Kim KT, Ku YM, Park SH, Kim YS, Lee DG, et al. Clinical role of interstitial pneumonia in patients with scrub typhus: A possible marker of disease severity. J Korean Med Sci 2004;19:668-73.
Chaudhary M, Mir MA, Ayub SG; Protocol Group. Safety and efficacy of a novel drug elores (ceftriaxone sulbactam disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: A post-marketing surveillance study. Braz J Infect Dis 2017;21:408-17
Chaudhary M, Payasi A. Incidence, prevalence and control of multidrug resistant (MDR) carbapenemase producing Acinetobacter baumanii in Indian intensive care units. J Pharm Res 2013;7:175-80.
Sathe P, Maddani S, Kulkarni S, Munshi N. Management of ventilator associated pneumonia with a new antibiotic adjuvant entity (ceftriaxone sulbactam disodium edetate)-a novel approach to spare carbapenems. J Crit Care 2017;41:145-9.
Chaudhary M, Payasi A. Synergy of a novel antibiotic adjuvant entity against multi drug resistant Enterobacteriaceae. Am J Infect Dis 2013;9:94-103.
Chaudhary M, Payasi A. A randomized, open-label, prospective, multicenter Phase-III clinical trial of Elores in lower respiratory tract and urinary tract infections. J Pharm Res 2013;6:409-14.
Lee CS, Doi Y. Therapy of infections due to carbapenem-resistant gram-negative pathogens. Infect Chemother 2014;46:149-64.
Lambert RJ, Hanlon GW, Denyer SP. The synergistic effect of EDTA/antimicrobial combinations on Pseudomonas aeruginosa. J Appl Microbiol 2004;96:244-53.
Singh AP, Gupta DU, Das S. Monitor the use of antibiotics in intensive care units with special focus on restricted antibiotics in tertiary care hospital of India. Asian J Pharm Clin Res 2016;9:256-9.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
